Company Focus
Moderna
Latest Moderna News
Biotechnology
Cambridge, USA-based mRNA vaccines company Moderna today announced the addition of a chief operating officer (COO) role to support the increasing scale and diversification of the company. 30 September 2026
Related News
Insights
Company Spotlight
A UK life science investor, listed in London and managed by a team the Wellcome Trust founded in 2012, that builds and funds biotech companies from British science and is now focused on returning at least £250 million ($336.8 million) to shareholders from a portfolio of 15 companies.
Latest News & Features of interest to Moderna
Biotechnology
Swedish immuno-oncology firm Alligator Bioscience has announced the appointment of Johan Giléus as Alligator’s new chief executive (CEO), effective 1 January 2027. 5 October 2026
Biotechnology
Significant research news last week included Mirum Pharmaceuticals releasing positive Phase III data for its hepatitis delta antibody brelovitug and Merck & Co Phase III results for its tulisokibart in hidradenitis suppurativa. Also of note, UK pharma major AstraZeneca said it will invest $2 billion in US biotech Summit Therapeutics, and France’s Sanofi announced an expanded global alliance with Regeneron in next-generation antibodies. 4 October 2026
Biotechnology
Privately-held Italian drugmaker Italfarmaco and Japan’s JCR Pharmaceuticals have entered an exclusive license agreement to develop and commercialize JR-141 for the treatment of Hunter syndrome in the USA, Europe, and Latin America, pending regulatory approval. 3 October 2026
Pharmaceutical
The US Food and Drug Administration (FDA) approved Camzyos (mavacamten), from Bristol Myers Squibb for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more. 2 October 2026
Pharmaceutical
US pharma major Johnson & Johnson has made no secret of its ambition to lead the oncology field. The Pharma Letter put that ambition to the company's own discovery leadership during a media site visit to J&J's Beerse campus in Belgium on September 29, 2026 — the company's largest R&D and supply chain site in Europe, and historically the home of Janssen Pharmaceutica, founded by Paul Janssen in the 1950s. 2 October 2026
Pharmaceutical
Eli Lilly has presented detailed results from the Phase III ACHIEVE-4 trial showing its oral GLP-1 receptor agonist Foundayo (orforglipron) met the primary endpoint of non-inferiority on major adverse cardiovascular events (MACE) against titrated insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. 2 October 2026
Pharmaceutical
The US Institute for Clinical and Economic Review (ICER) has posted its revised Evidence Report assessing the comparative clinical effectiveness and value of baxdrostat (Baxfendy, from AstraZeneca ) and lorundrostat (from Mineralys Therapeutics) for hypertension. 2 October 2026
Biotechnology
UK pharma major AstraZeneca nd Japanese drugmaker Daiichi Sankyo plan to test Datroway (datopotamab deruxtecan) with ivonescimab in a Phase III trial in first-line triple-negative breast cancer, under a new collaboration with US biotech Summit Therapeutics. 2 October 2026
Pharmaceutical
The UK's National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Tryngolza (olezarsen), from Sobi, the Swedish rare disease specialist, to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales whose response to diet and conventional triglyceride-lowering treatments, such as statins and fibrates, has been inadequate. 1 October 2026
Biotechnology
Swiss clinical-stage biotech Numab Therapeutics, which is advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, today announced the appointment of Dr Rajesh Chopra as chief scientific officer (CSO). 1 October 2026
Latest In Brief for Moderna
Biotechnology
US pharma major AbbVie is nearing an all-cash deal to acquire clinical-stage biotech Apogee Therapeutics for roughly $10.9 billion. 20 June 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze